SUSTAINABLE DEVELOPMENT
Innovate. Sustain. Transform.
Save up to 30% on top Physical Sciences & Engineering titles!
Therapeutic Drug Monitoring
Newer Drugs and Biomarkers
- 1st Edition - June 7, 2012
- Editor: Amitava Dasgupta
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 3 8 5 4 6 7 - 4
- eBook ISBN:9 7 8 - 0 - 1 2 - 3 8 5 4 6 8 - 1
Therapeutic Drug Monitoring: Newer Drugs and Biomarkers features timely topics such as the monitoring of classical and newer drugs, pharmacogenomics and the application of biomar… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteTherapeutic Drug Monitoring: Newer Drugs and Biomarkers features timely topics such as the monitoring of classical and newer drugs, pharmacogenomics and the application of biomarkers in therapeutic drug monitoring. This reference also discusses the limitations of current commercially available immunoassays for therapeutic monitoring. It presents new and sophisticated techniques used for proper determination of blood levels and the clinical utility of therapeutic drug monitoring of contemporary drugs. Written by leading international experts and geared toward clinical pathologists, toxicologists, clinical chemists, laboratory professionals and physicians, this book is an essential resource on the current practice of therapeutic drug monitoring in improving patient safety.
- Includes both the technical and clinical issues associated with therapeutic drug monitoring
- Discusses the utility of therapeutic drug monitoring of newer drugs such as antiretroviral agents, anticonvulsants, antidepressants etc.
- Provides up-to-date information on issues in pharmacogenomics and personalized medicine with emphasis on therapy with warfarin, certain anticancer drugs and antidepressants
- Covers important content on the limitations of commercially available immunoassays (chemical tests) for therapeutic drug monitoring and additional analytical techniques
Clinical pathologists, toxicologists, pharmacologists, laboratory professionals and clinical chemists
Dedication
Preface
Contributors
Chapter 1. Introduction to Therapeutic Drug Monitoring: Frequently and Less Frequently Monitored Drugs
Introduction
Drugs that Require Therapeutic Drug Monitoring
Benefits of Therapeutic Drug Monitoring
Pathophysiological Conditions and other Factors that Affect Drug Concentrations
Therapeutic Drug Monitoring of Various Drug Classes
Conclusions
References
Chapter 2. Effects of Pre-analytical Variables in Therapeutic Drug Monitoring
Introduction
Specimen Type
Factors that Affect Therapeutic Drug Monitoring Results
Protein Binding Alteration: In Vivo and In Vitro
Specimen Collection Site
Volume of Specimen Collected
Glass versus Plastic Tubes for Collection of Blood
Serum versus Plasma Specimen for Therapeutic Drug Monitoring
Suitability of Serum Separator Collection Tubes for Specimen Collection for Drug Monitoring
Sample Preparation Steps
Conclusions
References
Chapter 3. Analytical Techniques used in Therapeutic Drug Monitoring
Introduction
A General Classification of Analytical Methods
Understanding and Minimizing Measurement Uncertainty in the Clinical Laboratory
Immunoassays
Gas and Liquid Chromatography
Mass Spectrometry and LC-MS/MS Application to TDM
Conclusions
References
Chapter 4. Clinical Utility of Free Drug Monitoring
Introduction
Free Concentrations versus Total Concentrations
Pharmacokinetic Consequences of Drug–Protein Binding
Monitoring Free Concentrations of Classical Anti-Epileptics
Monitoring Free Concentrations of Antibiotics, Antimalarials and Antiretrovirals
Monitoring Free Concentrations of Immunosuppressants
Monitoring Free Concentrations of Other Drugs
Applications and Methods for Monitoring Free Drug Concentrations
Alternative Methods
Conclusions
References
Chapter 5. Current Practice of Therapeutic Drug Monitoring: Dose Adjustment of Drugs using Pharmacokinetic Models
Introduction
Bayesian Estimation
Examples of Clinical Transferability
Conclusion
References
Chapter 6. An Introduction to Personalized Medicine
Introduction
Overview of Classical Sequence Variation Profiling Techniques
Recent Molecular Profiling Technologies
Select Biomarkers in Pharmacogenomics
Translational Approaches Associated with Pharmacogenomics and Personalized Medicine
Conclusions
References
Chapter 7. Application of Ultra-High Throughput Sequencing and Microarray Technologies in Pharmacogenomics Testing
Introduction
DNA Microarray
Pharmacogenetic Testing and Healthcare
DNA Microarray Platforms
Microarrays and Genotype
Microarrays in Clinical Diagnosis
Sequencing Technologies – The First Generation
Sequencing Technologies – Next Generation
Exon Capture and Oligonucleotide-Based Genomic Selection
Microarray Technology versus Deep Sequencing
Sequencing and Implications for Pharmacogenomics Testing
Conclusions
References
Chapter 8. Pharmacogenomics and Warfarin Therapy
Introduction
The Potential of Pharmacogenetics for Warfarin
Pharmacology
Non-Genetic Factors Affecting Warfarin Dosing
Clinical Relevance
Cost-Effectiveness of Pharmacogenomics Testing in Warfarin Therapy
New Medications to Replace Warfarin
Conclusions
References
Chapter 9. Applications of Pharmacokinetic and Pharmacodynamic Principles to Optimize Drug Dosage Selection: Example of Antibiotic Therapy Management
Introduction
Pharmacokinetics and Pharmacodynamics
Applied Pharmacokinetic/Pharmacodynamic Modeling
Conclusions
References
Chapter 10. Guidelines for the Monitoring of Vancomycin, Aminoglycosides and Certain Antibiotics
Introduction
Vancomycin: Overview
Aminoglycosides: Overview
Therapeutic Drug Monitoring of Beta-Lactam Antibiotics
Therapeutic Drug Monitoring of Sulfonamides and Trimethoprim
Therapeutic Drug Monitoring of Chloramphenicol and Tetracycline
Therapeutic Drug Monitoring of Quinolones
Therapeutic Drug Monitoring of Macrolides
Therapeutic Drug Monitoring of Antimycobacterial Agents
Conclusions
References
Chapter 11. Challenges in Therapeutic Drug Monitoring of Digoxin and Other Anti-Arrhythmic Drugs
Introduction
Challenges in Therapeutic Drug Monitoring of Digoxin
Therapeutic Drug Monitoring of Other Anti-Arrhythmic Drugs
Challenges in Monitoring Class IV Anti-Arrhythmic Drugs
Chromatographic Methods for Determining Multiple Anti-Arrhythmic Drugs Simultaneously
Conclusions
References
Chapter 12. Therapeutic Drug Monitoring of Classical and Newer Anticonvulsants
Introduction
Pathophysiology of Epilepsy
Anti-Epileptic Drug Monitoring
Indications for Measuring a Drug Level
Therapeutic Drug Monitoring of Classical AEDs
Newer Anticonvulsants
Therapeutic Drug Monitoring of Eslicarbazepine Acetate
Therapeutic Drug Monitoring of Felbamate
Monitoring of Gabapentin
Therapeutic Drug Monitoring of Lacosamide
Therapeutic Drug Monitoring of Lamotrigine
Therapeutic Drug Monitoring of Levetiracetam
Therapeutic Drug Monitoring of Oxcarbazepine
Therapeutic Drug Monitoring of Pregabalin
Therapeutic Drug Monitoring of Rufinamide
Therapeutic Drug Monitoring of Stiripentol
Therapeutic Drug Monitoring of Tiagabine
Therapeutic Drug Monitoring of Topiramate
Therapeutic Drug Monitoring of Vigabatrin
Therapeutic Drug Monitoring of Zonisamide
Analytical Methods for Monitoring of AEDs
Conclusion
References
Chapter 13. Challenges in Therapeutic Drug Monitoring of Classical Tricyclic and Newer Antidepressants: Analytical and Pharmacogenetics Considerations
Introduction
Tricyclic Antidepressants
Newer Antidepressants
Pharmacogenetics Considerations in TDM of Antidepressants
Conclusions
References
Chapter 14. Therapeutic Drug Monitoring of Selected Anticancer Drugs: Pharmacogenomics Issues
Introduction
Traditional Therapeutic Drug Monitoring for Anticancer Drugs
Newer Approaches to Personalized Dosing and Treatment with Anticancer Agents: Pharmacogenetics
Pharmacogenetic Considerations for Specific Anticancer Agents
Anti-EGFR Tyrosine Kinase Inhibitors
Conclusions
References
Chapter 15. Immunosuppressive Drug Monitoring: Limitations of Immunoassays and the Application of Liquid Chromatography Mass Spectrometry
Introduction
Application of Immunoassays and LC-MS to Immunosuppressive Drug Monitoring
Therapeutic Drug Monitoring of Calcineurin Inhibitors (Cyclosporine and Tacrolimus)
Therapeutic Drug Monitoring of Mammalian Target of Rapamycin (MTOR) Inhibitors (Sirolimus and Everolimus)
Therapeutic Drug Monitoring of Mycophenolic Acid
Conclusions
References
Chapter 16. Biomarkers: The Link between Therapeutic Drug Monitoring and Pharmacodynamics of Immunosuppressants
Introduction
Specific Pharmacodynamic Markers
Global Markers of Response to Immunosuppressants
Biomarker Signatures Related to Tolerance
Conclusions
References
Chapter 17. Therapeutic Drug Monitoring of Antiretroviral Drugs in the Management of Human Immunodeficiency Virus Infection
Introduction
Therapeutic Targets of Therapeutic Drug Monitoring (TDM) in HIV-infected Patients
Current Approach to TDM in the Management of Therapy in HIV-infected Patients
Current Methodologies in TDM of Antiretroviral Drugs
TDM of Antiretroviral Drugs by Classes
Challenges in Practical Application of TDM in Managing Patients with HIV
Conclusion
References
Chapter 18. Drug Testing in Pain Management
Introduction
Use of Opioids in Pain Management
Analytical Methods for Drug Testing
Specimen Tampering
Metabolism of Opioid Analgesics
Challenges in Drug Testing in Pain Management
Conclusions
References
Chapter 19. Effect of Herbal Supplement–Drug Interactions on Therapeutic Drug Monitoring
Introduction
Herbal Supplements and Pharmacokinetics
Pharmacokinetic Interactions Involving Herbal Supplements
Contamination of Herbal Supplements
Analytical Interferences Caused by Some Herbal Supplements
Conclusions
References
Index
- No. of pages: 468
- Language: English
- Edition: 1
- Published: June 7, 2012
- Imprint: Academic Press
- Hardback ISBN: 9780123854674
- eBook ISBN: 9780123854681
AD
Amitava Dasgupta
Amitava Dasgupta received his Ph. D in chemistry from Stanford University and completed his fellowship training in Clinical Chemistry from the Department of Laboratory Medicine at the University of Washington School of Medicine at Seattle. He is board certified in both Toxicology and Clinical Chemistry by the American Board of Clinical Chemistry. Currently, he is a tenured Full Professor of Pathology and Laboratory Medicine at the University of Kansas Medical Center and Director of Clinical Laboratories at the University of Kansas Hospital. Prior to this appointment he was a tenured Professor of Pathology and Laboratory Medicine at the University of Texas McGovern medical School from February 1998 to April 2022. He has 252 papers to his credit. He is in the editorial board of four journals including Therapeutic Drug Monitoring, Clinica Chimica Acta, Archives of Pathology and Laboratory Medicine, and Journal of Clinical Laboratory Analysis.
Affiliations and expertise
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United StatesRead Therapeutic Drug Monitoring on ScienceDirect